Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Positive topline data from Phase 3 BROOKLYN trial shows obicetrapib significantly reduces LDL-C by 36.3% at 12 weeks and 41.5% at 52 weeks in HeFH patients, with well-tolerated safety profile. Over 50% achieved LDL-C below 70 mg/dl, and reductions in non-HDL-C, ApoB, and Lp(a) were statistically significant. The trial evaluated 10 mg obicetrapib vs. placebo in 354 patients with HeFH on maximally tolerated lipid-lowering therapy.